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Abstract
Cystic fibrosis (CF), the most common life-shortening genetic disorder in Caucasians, affects
approximately 70 000 individuals worldwide. In 1998, the Cystic Fibrosis Foundation (CFF)
launched the CF Therapeutics Development Network (CF-TDN) as a central element of its
Therapeutics Development Programme. Designed to accelerate the clinical evaluation of new
therapies needed to fulfil the CFF mission to control and cure CF, the CF-TDN has conducted 75
clinical trials since its inception, and has contributed to studies as varied as initial safety and proof
of concept trials to pivotal programmes required for regulatory approval. This review highlights
recent and significant research efforts of the CF-TDN, including a summary of contributions to
studies involving CF transmembrane conductance regulator (CFTR) modulators, airway surface
liquid hydrators and mucus modifiers, anti-infectives, anti-inflammatories, and nutritional
therapies. Efforts to advance CF biomarkers, necessary to accelerate the therapeutic goals of the
network, are also summarised.
STRUCTURE OF THE NETWORK, CFF PARTNERSHIP, INDUSTRY
PARTNERSHIPS, OPERATIONAL ISSUES THAT FOSTER SUCCESS
Cystic fibrosis (CF), the most common life-shortening genetic disorder in Caucasians,
affects approximately 70 000 individuals worldwide and meets the US Food and Drug
Administration (FDA) definition of an orphan disease.1 Historically, the limited number of
patients at each clinical site led to underpowered research studies2 and was a critical barrier
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to development and regulatory approval of new therapies. Hence, the Cystic Fibrosis
Foundation (CFF) launched the CF Therapeutics Development Network (CF-TDN) in 1998
to accelerate the clinical evaluation of new CF therapies.3,4 From its inception, the CF-TDN
was organised to provide necessary infrastructure to promote efficient study conduct. In
addition, patient safety has always been the highest priority.3 From the beginning, the
programme was composed of Therapeutic Development Centers (TDCs) across the USA, a
clinical and data coordinating centre located at Seattle Children’s Research Institute, and a
number of resource centres with expertise in interpretation or performance of specialised
outcomes measures (microbiology, imaging, infant lung function testing, inflammatory
mediators, sweat testing, CF transmembrane conductance regulator (CFTR) detection and
cytology interpretation) (see online supplementary figure S1). To maintain scientific
integrity and safety of CF-TDN studies, there is a Steering Committee, protocol review of
all multi-center trials, and review of presentations and publications from CF-TDN studies
(see online supplementary figure S2). The CFF-supported Data Safety Monitoring Board
located at the University of Arizona has oversight of clinical trials at all centres. The TDCs
are selected by a competitive, peer-reviewed application process from the 120 US CF care
centres4,5 and receive infrastructure support for a research coordinator and other necessary
staff. As a result, TDCs have been able to retain well trained, experienced research staff
teamed with site investigators. Over the past 15 years, the CF-TDN has successfully
completed over 75 clinical trials along the entire developmental path from phase I to phase
III registration trials. The goal to bring new therapies to the CF community has been
achieved with FDA approval of several therapies (table 1).6 A key factor in the success of
the CF-TDN has been its partnership with industry, providing a full range of consultative
services from the earliest discussions about protocol development through critical protocol
review to feedback on the industry/CRO experience from the study site perspective. Above
all, industry sponsors value the CF-TDN’s experience in the conduct of CF clinical research
in the USA.
The coordinated efforts of the CF-TDN also include the development of novel outcome
measures (below), use of banked specimens and data to conduct ancillary studies,7,8 and
development of novel approaches to study design and analyses.9 In addition, the network has
focused on a quality improvement (QI) initiative based upon ground-breaking work of the
CF care centre programme.5,10 The need for improved communications and a QI programme
became essential when the CF-TDN expanded from 8 to 77 TDC sites from 1998 to 2009,
encompassing a population of 19 000 patients. Communication was improved using
quarterly newsletters, conference calls, annual in-person meetings, and the creation of the
CF-TDN website, CF Clinical Research Net, which tracks site study activity, provides tools
for site training and programme enhancement, hosts committee work, posts news and
information regarding studies and network programmes, and provides access to the network
database. A commitment to QI for all aspects of clinical studies has paralleled the growth in
network size. Here we summarise recent progress of the network across key therapeutic
areas (see CF-TDN Pipeline depicted on the front cover).
CFTR MODULATORS
CFTR modulators have brought a personalised approach to altering the basic defect in the
disease using gene class specific therapy (see reviews11–15). By grouping CFTR mutations
into causative classes, specific approaches can be developed that address the underlying
molecular defect on an individual patient level (figure 1), and serves as a paradigm for the
treatment of other genetic diseases.16 The evaluation of these novel agents required
expertise in proof-of-concept clinical trial design, biomarkers of pharmacological activity,
and clinical outcome measures in an entirely new therapeutic area, and were promoted by
close partnerships between the pharmaceutical industry and the CFF. Recent results have
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firmly established that rescue of CFTR-mediated anion transport can result in marked
clinical benefit if CFTR functional improvement is sufficient,6 a concept likely to be a major
contributor to CF-TDN efforts in the future.
CFTR modulator therapies have been directed towards specific disease-causing mutations
and the molecular pathways that underlie their cause.12,16 A crucial phase II trial that tested
the CFTR potentiator ivacaftor (Kalydeco, VX-770) in 40 patients with CF with at least one
copy of the G551D mutation, a relatively common class 3 gating mutant, in a two-part
randomised placebo-controlled design was the first to definitively establish that CFTR
functional rescue detected by simultaneous improvement in nasal potential difference (NPD)
and sweat chloride could result in meaningful changes in lung function.17 This was rapidly
followed by two phase III trials in patients with G551D CF to establish the clinical effect of
ivacaftor during a sustained period. In a trial in older children and adults (aged 12 and
above), forced expiratory volume in 1 s (FEV1) improved 10.5% at 24 weeks, an effect
durable at 48 weeks and accompanied by a 55% reduction in the probability of experiencing
a pulmonary exacerbation, a 3.1 kg weight gain (compared with 0.9 kg in the placebo
group), and improved respiratory symptoms as assessed by the CFQ-R, a patient reported
quality-of-life index.6 As with phase II testing, sweat chloride improved by around 48 mEq/
litre, and mean concentration was around 55 mEq/litre, a level below the traditional
diagnostic threshold of CF (60 mEq/litre). Similar results were reported in a study of
patients with G551D aged 6–12,18 enabling prompt approval of the drug for patients with
G551D CF aged 6 and above by the FDA and European regulatory authorities. The CF-TDN
will support additional studies to evaluate the safety and pharmacokinetics of ivacaftor in
younger patients with CF (aged 2–5), which could also begin to assess the effects of early
CFTR rescue on the pancreas. The rapid approval and availability of ivacaftor has also
enabled the G551D observational study (GOAL), which will assess the clinical effects of
ivacaftor in patients with G551D CF post-approval, including the response of several
mechanistic biomarkers such as sweat rate, mucociliary clearance imaging, gastrointestinal
pH, and sputum measures of inflammation and microbiology; these studies are intended to
advance our understanding of the effects of efficacious CFTR modulation on disease-
relevant biomarkers and pathways. Since ivacaftor also exhibits robust activity in other rare
but clinically relevant CFTR gating mutations, the drug is also being studied in patients with
CFTR gating mutations other than G551D. Ivacaftor will also be tested in the archetype
conductance mutation R117H, which could establish whether potentiation of CFTR gating is
sufficient to partially ameliorate non-gating mutations, setting the stage for other studies
involving rare mutations localised to the cell surface.
Since ivacaftor alone is not sufficient to meaningfully alter CFTR activity in patients with
CF homozygous for F508del,19 a class 2 mutant and the most common CFTR mutation,
‘correctors’ of CFTR misfolding are required to augment localisation of the F508del CFTR
mutation to the cell surface. The CFTR correctors lumacaftor (VX-809, Vertex
Pharmaceuticals, Cambridge, Massachusetts, USA) and VX-661 (Vertex Pharmaceuticals)
have entered clinical testing within the CF-TDN for this purpose. While monotherapy with
lumacaftor in adults homozygous for the F508del mutation only modestly reduced sweat
chloride (8 mEq effect vs placebo at the highest dose tested (200 mg)) and did not improve
lung function or NPD, evidence of sweat chloride improvement, albeit small in magnitude,
suggested correction of the F508del CFTR protein was possible.20 To improve upon the
effects of a corrector alone, lumacaftor is presently being tested at higher doses in a
threepart study alone and in combination with ivacaftor, thereby evaluating the effects of
augmenting CFTR channel gating following partial restoration of CFTR to the cell surface, a
strategy justified by preclinical research21,22 and the known effects of the F508 deletion on
gating in addition to cellular processing.23 Interim results through part 2 of the study have
indicated that high doses of lumacaftor combined with ivacaftor improves FEV1 by 7.4%,
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and have recently provided the basis for a pivotal programme to evaluate combination
therapy in patients with CF homozygous for F508del that will necessitate involvement in a
many sites, including those beyond the network infrastructure. TDCs are also involved in
testing the CFTR corrector VX-661 alone and in combination with ivacaftor as an alternate
CFTR corrector to lumacaftor. In total, the combination of CFTR potentiators and correctors
could result in effective therapies in a large proportion of patients with CF (table 2).
The CFTR modulator class also includes treatment strategies directed towards premature
termination codons (class 1 mutations). Following the discovery that aminoglycoside
antibiotics can induce readthrough premature termination codons resulting in full-length
functional protein,24 an initial TDN network study focused on topical administration of
aminoglycosides25; while bioactivity was not detectable and conflicted with other single-
centre studies,26–28 this trial provided experience evaluating CFTR modulators helpful for
subsequent studies, including those evaluating the small molecule ataluren (PTC124,
premature termination codon therapeutics). Based on efficacy in vitro29 and in animal
models,30 ataluren was studied in a series of conflicting phase II trials,31–33 one of which
involved the TDN network.32 Results of a long-term study showed no improvement in FEV1
% predicted, the primary endpoint, but did demonstrate a small effect on lung function in a
predefined subset of individuals who were not treated with inhaled antibiotics, which can
alter the efficacy of ataluren.34 While the clinical status of ataluren remains uncertain at
present, given the strong foundation of translational readthrough as a therapeutic strategy for
CF and many other genetic diseases, studies involving this compound and other readthrough
approaches within the CF-TDN are likely in the future.
AIRWAY SURFACE LIQUID DEPTH AND MUCUS MODIFICATION
The rationale supporting the development of therapeutics targeting airway surface liquid
(ASL) volume and mucus properties comes from basic research on the pathogenesis of CF
lung disease.35 Numerous experimental models support the central role of CFTR as both a
chloride channel and as a regulator of other ion channels in airway epithelia.36,37 Disruption
of CFTR activity, in turn, has been linked to the development of defective mucus clearance
via depletion of ASL volume and mucus dehydration.38 These and perhaps other distinct
effects on airways defence may ultimately explain the initial, profound vulnerability to
chronic bacterial airways infection that exists in CF, while also contributing to disease
progression.
Approaches to increase fluid secretion and/or reduce fluid reabsorption to augment impaired
mucociliary clearance in CF represent a major line of therapeutics that address fundamental
physiological deficits in CF, and are not restricted to specific CFTR mutations nor the
uncertainties of gene transfer. A multifaceted approach via collaborations between scientists,
industry, the CF Foundation, and the Therapeutic Development Network, utilising different
therapeutic targets, has been pursued to maximise the chance of success. These alternative
ASL restoring therapeutics can be grouped into those that promote increases in ASL volume
and mucus hydration via osmotic mechanisms (eg, hypertonic saline; Bronchitol, Pharmaxis,
Frenchs Forest, Australia), by reducing fluid reabsorption from the airway lumen through
inhibition of the epithelial sodium channel (eg, GS9411, Gilead Sciences, Foster City,
California, USA) or by increasing chloride secretion via various non-CFTR pathways (eg,
denufosol, Inspire Pharmceuticals, Raleigh, North Carolina, USA; Moli 1901, Lantibio,
Chapel Hill, North Carolina, USA; SPI-881, Sucampo, Bethesda, Maryland, USA). Within
the osmotic hydrator class of therapies, hypertonic saline is already available,39,40 and
successful completion of phase III trials of dry-powder mannitol in the USA and abroad led
to the recent approval for use in Australia and the EU, whereas FDA review is presently
underway in the USA.41–43 Addressing abnormal CF mucus, marked by the approval of
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recombinant human DNAse (Pulmozyme, Genentech, San Francisco, California, USA),44
has also had renewed interest, and is likely to lead to new lines of investigation supported by
the network.
The concept of targeting sodium hyperabsorption, and thereby improving ASL hydration,
first emerged more than three decades ago.45,46 The earliest attempts at manipulating
sodium transport in the airways of patients with CF utilised inhaled amiloride.47–49
Treatment with amiloride was ultimately unsuccessful, likely due to inadequate potency and
duration of action. Since then, newer agents with improved pharmacokinetic and
pharmacodynamic properties have been developed, and early phase trials have been
conducted to test their safety.50 Additional research with the latest molecules should be
available soon for testing within the CF-TDN.
Stimulation of chloride secretion in the absence of CFTR can be accomplished in vitro and
in vivo using agents that stimulate alternative chloride channels, including TMEM16a and
others activated by calcium.51 Testing of an orally dosed prostone (cobiprostone, Sucampo)
was conducted by the CF-TDN nearly 10 years ago. Although this study did not demonstrate
a clear chloride secretory response, a related compound was eventually approved as a
chloride secretagogue for the treatment of chronic constipation, and this study along with
other early efforts informed the network on the use of NPD and other techniques now
commonly used in CF-TDN network studies.25,52 Moli1901 (Lantibio) showed early
promise as a chloride transport activator in US and European studies,53 but has not been
pursued further due to formulation issues. Denufosol (Inspire Pharmaceuticals), a P2Y2
agonist designed to restore chloride transport and increase mucociliary clearance, also
yielded promising results in early phase studies,54,55 but ultimately failed after the conduct
of two phase III trials.56,57 Reflection on lessons learned and research into the potential
cause of this failure has been undertaken and will educate the search for additional ASL
modifying agents.
ANTI-INFECTIVES
Chronic bacterial infections of the CF airways with resistant organisms, including multidrug
resistant (MDR) Pseudomonas aeruginosa and other intrinsically resistant organisms such as
Burkholderia cepacia complex, Stenotrophomonas maltophilia and Achromobacter species
remain a major therapeutic challenge in CF.58 For example, the current rate of MDR P
aeruginosa among patients with CF is 9.8%.59 Because of the severity and relentless nature
of CF airway infections and the need to develop new treatment approaches to alleviate the
development of resistance, an important focus of TDN-supported studies has been in the
area of anti-infectives. Unfortunately, few new anti-microbials directed against P aeruginosa
have been developed in the past two decades. Thus, recent anti-infective strategies have used
currently available antimicrobials in new ways. In addition, novel approaches to treatment
have been developed, including suppression of chronic infections and early therapy to
eradicate infections prior to irreversible infection.
A sentinel agent in the development of new antimicrobial strategies for treatment of P
aeruginosa in CF was tobramycin inhalation solution (TOBI, Novartis Pharmaceuticals, East
Hanover, New Jersey, USA). Inhalation of antibiotics allows high concentrations of active
drug at the site of infection, while minimising side effects. Inhaled tobramycin was tested in
two trials including a total of 520 subjects over the age of 6 years. The trials demonstrated
improvement in lung function and decrease in bacterial colony counts, and supported the
drug’s FDA approval in 1994. Although early in the formation of the network, the concept
of inhaled suppressive antibiotics and the actual study design of the inhaled tobramycin
trials have served as a model for other antimicrobial agents tested by TDCs. Aztreonam
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lysinate for inhalation (AZLI, Cayston, Gilead Sciences) was initially developed through
support of the CFF and the clinical trials were performed through the TDN. Since its
approval by the FDA, AZLI has been rapidly used by the CF population, demonstrating the
intense need for new antimicrobial therapies. To extend efficacy to alternative organisms, a
phase IV trial of AZLI for patients with CF and B cepacia complex infections was recently
completed and Gilead is conducting an ongoing phase IV CFF Patient Registry-based study
of antibiotic resistance. Other agents that have been formulated for airway administration
and are currently in the CF Foundation Therapeutics Pipeline include tobramycin inhaled
powder (TOBI Podhaler, Novartis Pharmaceuticals), inhaled levofloxacin (Aeroquin Axcan
Pharmaceuticals, San Diego, California, USA), and inhaled liposomal amikacin (Arikace,
Insmed, Monmouth Junction, New Jersey, USA), all of which are in phase III trials and offer
improved convenience, delivery, and durability. Similarly, ciprofloxacin inhaled powder
(Bayer Schering Pharma AG, Berlin-Wedding, Germany), has recently completed a phase II
trial in CF, but has not yet begun phase III testing.
Another example of using currently available antimicrobials is the novel use of azithromycin
in the management of CF airway infections. Although active in vitro against Staphylococcus
aureus and Haemophilus influenzae, azithromycin is not considered active against the most
typical gram-negative CF pathogens. However, studies developed through Cystic Fibrosis
Foundation Therapeutics have demonstrated clinical response to three times a week
administration of azithromycin. This was initially shown in a large clinical trial in patients
with CF and P aeruginosa infection who were over the age of 6 and subsequently confirmed
in younger children and those uninfected with P aeruginosa.60,61 The exact mechanism of
action has not been demonstrated but patients responded with an improvement in FEV1 and
a decreased frequency of pulmonary exacerbations.
Studies within the TDN have examined the role of early antibiotic therapy in eradicating
early infection and delaying the establishment of chronic infections in young children.62–64
The EPIC trial was a multicentre randomised trial comparing one-drug or two-drug therapy
(TOBI with or without oral ciprofloxacin) with either cycled or culture-dependent
administration to eradicate early P aeruginosa infection. It demonstrated equal efficacy and
safety in all arms without emergence of multiple antibiotic resistant organisms.65,66
A new antimicrobial soon to begin phase II testing is KB001 (KaloBios Pharmaceuticals,
South San Francisco, California, USA), a monoclonal antibody fragment directed against the
PcrV protein of the type 3 secretion system of P aeruginosa.67 Other antimicrobial therapies
on the horizon include trials for the management of methicillin-resistant S aureus and
nontuberculous mycobacteria, and intravenous administration of gallium, an agent that is not
a conventional antibiotic but has antimicrobial properties and is currently used by
radiologists for nuclear medicine scans.
ANTI-INFLAMMATORY THERAPIES
Neutrophil-dominated airway inflammation is a hallmark of CF lung disease (see previous
reviews68–71); thus, evaluating drugs that target inflammation is a major emphasis of the
network. Corticosteroids and high-dose ibuprofen, each broad spectrum inhibitors of pro-
inflammatory signalling, were two of the first anti-inflammatory drugs studied in CF. Both
demonstrated clinical benefit,72–74 but side effects and other considerations have limited
their use.75–77 However, the evidence that these anti-inflammatory agents can slow the
progression of CF lung disease, particularly in children, suggests that strategies to modulate
lung inflammation can be beneficial.
The CF-TDN has devoted significant resources to evaluating anti-inflammatory treatments.
Among those successful include azithromycin, hydroxychloroquine which has been shown
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to reduce pulmonary exacerbations and improve lung function in patients with CF, without
significantly affecting lower airway bacterial density60,61 (see Anti-infectives section). The
evidence suggests that azithromycin may act as an anti-inflammatory or immunomodulatory
agent, which may also explain its efficacy in chronic obstructive pulmonary disease.78 In a
trial of azithromycin in patients with CF chronically infected with P aeruginosa, there was a
modest reduction in sputum neutrophil elastase activity in favour of the azithromycin
group.61 In a subsequent clinical trial in patients with CF, 6–18 years of age and uninfected
with P aeruginosa, azithromycin significantly reduced circulating neutrophil counts and
systemic markers of inflammation, including C-reactive protein, serum amyloid A and
calprotectin.79
Several CF-TDN-supported studies evaluating more targeted anti-inflammatory agents have
been largely unsuccessful, and a few were associated with detrimental side effects. A
notable example of the latter was a trial testing the leukotriene B4 receptor antagonist
amelubant (Boehringer Ingelheim, Bracknell, UK) in patients with CF and mild to moderate
lung disease.80 The study was terminated early due to a significant increase in the frequency
of pulmonary exacerbations in adults receiving amelubant. This trial gave the CF
community pause, providing a potent reminder that modulating inflammation is not without
risks. Based on preclinical models and associated clinical data,81 it was hypothesised that
treatment with interferon γ (IFNγ), a pleiotropic cytokine with immunomodulatory and
antimicrobial activities, would be beneficial in CF. However, a clinical trial with inhaled
IFN-γ1b (Actimmune, InterMune, Brisbane, California, USA) did not significantly improve
lung function, sputum bacterial density or sputum biomarkers of inflammation.82 The CF-
TDN network also sponsored studies of ‘low-hanging fruit’ anti-inflammatory compounds
(ie, available medications used for other inflammatory disorders), including the 3-
hydroxy-3-methyl coenzyme A reductase inhibitor simvastatin, the peroxisome proliferator-
activated receptor γ agonist pioglitazone, and the immunosuppressants methotrexate and
hydroxychloroquine. Data from these small, short studies were largely negative, while
methotrexate was associated with an intolerable adverse event profile.83–86 These
compounds are no longer being actively investigated, and indicate the complexities of a
targeted anti-inflammatory approach in CF lung disease. Additionally, recent 6-month
antioxidant trials of inhaled glutathione and oral N-acetylcysteine, a glutathione prodrug, did
not demonstrate positive effects either on inflammation, oxidative stress, or clinical
outcomes in patients with CF.87,88
Despite these disappointments, there are several ongoing studies of potential therapeutic
agents which address airway inflammation. Numerous studies have demonstrated an excess
burden of neutrophil-derived proteases in the CF airway and provide justification for
interventions that neutralise free neutrophil elastase activity or augment local antiprotease
levels. There has been renewed interest by the pharmaceutical industry to develop α1-
antitrypsin therapies in CF and clinical trials using more potent and efficacious formulations
are once again being planned. Antioxidant deficiencies remain a viable therapeutic target in
CF. A trial of a reformulated oral multivitamin supplement (AquADEKs), enriched with
several non-enzymatic antioxidants including β-carotene, mixed carotenoids, coenzyme
Q10, mixed tocopherols and selenium, will evaluate the effects of this antioxidant ‘cocktail’
on antioxidant levels and markers of oxidative stress. Other novel approaches include the
phosphodiesterase inhibitor sildenafil on airway inflammation and the effects of
sulforaphane (found in broccoli sprouts) on Nrf2 activation. Finally, a crucial question in the
new era of CFTR modulation is whether improving CFTR activity will have a detectable
impact on airway inflammation, a question addressed in the GOAL study (see CFTR
modulation section). The breadth of these studies using the CF-TDN network suggest
targeting inflammation in CF remains an attractive therapeutic approach, but optimising
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anti-inflammatory effects while minimising any detrimental impact on host defence remains
a key challenge.
NUTRITIONAL THERAPIES
Good nutrition is vital in CF,89 thus the TDN has investigated interventions to support
normal growth. Almost 90% of patients with CF are pancreatic insufficient90 and need life-
long treatment with pancreatic enzyme replacement therapy (PERT) to prevent malnutrition.
Because some pancreatic enzymes products were available before passage of the 1937 Pure
Food and Drug Act, drug companies had been allowed to manufacture and sell PERT
without prior FDA approval.91 In 1994 case reports of fibrosing colonopathy (FC) began to
appear; a subsequent analysis of CF Foundation Patient Registry data showed a strong
correlation between dose of PERT and the appearance of FC.92 Concerns regarding PERT
overuse, and other issues (eg, enteric coating and high-dose capsules) were raised as
potential contributing factors. As a result of these and other problems, in 2004 the FDA
issued notice that they would require a new drug application for PERT with a deadline of
April 2008,93 which was subsequently extended to 2010. The CF-TDN played a central role
in developing study protocols and implementing studies of the efficacy of PERT in this short
but urgent time window. Based on these efforts, the FDA has approved four oral delayed-
release PERTs, Creon,94 Zenpep,95,96 Pancreaze97,98 and Pertzye.99
A longitudinal observational study of nutritional status in infants (BONUS) is underway,
cosponsored by the National Institute of Health. With newborn screening for CF available in
all 50 states as of 2010, PERT is being used in a larger number of infants, yet dose response
has never been defined. A nested sub-study of BONUS will explore the efficacy of higher
and lower doses of PERT in infants.
All current PERTs are biological products derived from hog pancreas. Although current
FDA-approved products are no longer overfilled, have improved stability and are free of
enveloped viruses, non-enveloped viruses cannot be removed from the drug substance
without loss of efficacy. The CF-TDN has participated in studies of liprotamase, a novel
formulation of recombinant bacterial lipase, fungal protease and amorphous amylase that is
a non-biological PERT.100–103 The crystalline nature of some of its components confers
stability in an acid environment and makes a liquid preparation possible, providing a
potential advantage.
Progression of CF lung disease is linked to oxidative stress.104 Pancreatic insufficiency and
a diminished bile acid pool cause malabsorption of important antioxidants including fat-
soluble vitamins (vitamins A, D, E and K), carotenoids, tocopherols, selenium and
coenzyme Q10.105 A number of studies have shown that in patients with CF,
supplementation can correct many micronutrient deficiencies, although the evidence of
clinical benefit has been hampered by inconsistent study design.106 The CF-TDN
participated in developing an oral antioxidant-enriched multivitamin supplement that safely
increased systemic antioxidant levels107 and continues efforts to explore the benefits of this
nutritional approach to modify CF disease.
BIOMARKERS
Since the inception of the CF-TDN, the development of biomarkers to enhance CF clinical
trial planning and conduct has been at the forefront of network activity since alternatives to
hard clinical endpoints such as mortality and hospitalisation are not viable endpoints for
phase II and many phase III programmes.4 Biomarkers are ‘a characteristic that is
objectively measured and evaluated as an indicator of a normal biologic process, pathogenic
process, or pharmacologic response to a therapeutic intervention’.108 As such, CF-TDN-
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supported research has concentrated on the testing and validation of new biomarkers, linking
changes in biomarkers to established surrogate or clinical outcome measures, and refining
biomarker assessment techniques largely in the context of drug development. In addition,
the acquisition of high-quality longitudinal biospecimens linked to clinical data has been
incorporated into several CF-TDN clinical trials, leading to the development of rich
specimen banks for biomarker discovery. For example, these biobanks have been leveraged
by the CF research community to help define relationships between sputum inflammatory
markers (eg, interleukin-8, human neutrophil elastase) and clinical outcome measures (eg,
lung function),8,109 and to relate macrolide therapy to anti-inflammatory activity.79 The
capacity to interrogate samples obtained from multicentre studies that have been collected
with common standard operating procedures also increases the probability that results can be
successfully recapitulated in the clinic.
With the development of CFTR modulators, there has been a need to develop and refine
biomarkers related to augmented CFTR function. From these efforts, sweat chloride has
emerged as a robust, standardised and validated method to monitor the bioactivity of CFTR
potentiators and correctors.6,17,19,20,110 NPD has also performed reasonably well as a CFTR
biomarker,111–113 successfully detecting ivacaftor activity in patients with G551D CF. For
unclear reasons, neither CFTR biomarker has correlated with clinical outcomes (eg, lung
function, patient-reported outcomes (PROs), weight) on an individual patient basis. Ongoing
CF-TDN trials are underway to better understand this gap; one example is the GOAL study,
which includes the evaluation of functional biomarkers (see CFTR modulation section),
banking of serum, sputum, and urine linked to clinical data, and may help future biomarker
discovery.
A critical barrier that can potentially limit the extension of new therapies to the treatment of
infants and toddlers with CF (and other patients with very mild obstructive disease) is the
relative lack of biomarkers sensitive to small changes in these populations. It is a widely
held opinion that the greatest benefits conferred by many CF therapies would be expected in
the healthiest patients, prior to the development of irreversible lung injury. As one example
of success in this area, the CF-TDN developed standard operating procedures for the
conduct of infant pulmonary function tests for multicentre performance and analysis.114
These efforts were used to demonstrate improved lung function (change in FEV in 0.5 s) in
infants and toddlers with CF treated with 7% hypertonic saline compared with normal
saline, despite no detectable difference in pulmonary exacerbation rates between the two
treatment groups.115 Other CF-TDN studies in progress are geared towards accelerating
drug development in the infant population, including the Baby Observational and Nutritional
Study which also includes a biospecimen collection programme (see also above). Finally,
TDCs have participated in non-invasive techniques to monitor mild lung disease and
responses to intervention, including CT imaging55,116–119 and Lung Clearance Index
measurements in ivacaftor-treated patients with G551D CF. Further studies that link
sensitive disease biomarkers to clinical endpoints in the setting of new and established
therapies could help accelerate the development path required to bring therapies to the
healthiest patients with CF.
The TDN has played an instrumental role in advancing CF PROs and helping define their
role in drug development. This work was particularly instrumental during the development
of AZLI.120–122 PROs have also served as primary and secondary endpoints in pivotal trials
involving CF therapeutics; establishing the minimal clinically important difference for the
Respiratory Domain of the CF Questionnaire-Revised (CFQ-R) was critical to this effort.123
This work has paved the way for the incorporation of the CFQ-R into clinical trials of many
new CF treatment strategies.6,17,19,20,124,125 Future studies are planned to further refine CF
PROs, including the development of PROs for non-pulmonary disease manifestations,
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correlation of PRO results with other biomarkers, and the capture of information more
frequently (eg, daily diaries compared with 2-week recall that is a limitation of the current
CFQ-R).
FUTURE DIRECTIONS FOR THE NETWORK
As novel therapies emerge and evolve, clinical trials infrastructures must respond to the
expanding need for studies. The CF-TDN and its partner network, the European Society for
Cystic Fibrosis (ESCF) Clinical Trials Network, must maintain high-quality study conduct,
which will be optimised by providing the structure and tools for improvement through
webbased, QI programmes. These programmes are available to all sites with the requirement
that they participate in an assessment–prioritisation–implementation–reflection cycle and
report their results annually. A competitive application process will continue to sustain an
engaged network of participating sites that allows new sites to enter the network when they
demonstrate interest and capability, and permits adjusting network size to meet enrolment
projections for studies linked to the research pipeline.
The CF-TDN will continue to work cooperatively with the ESCF Clinical Trials Network
and the Canadian and Australian CF research communities to facilitate the conduct of
uniform protocols across multiple countries, to enrol larger sample sizes in a shorter time
period, and permit sufficient recruitment of subsets of patients with unique characteristics,
such as age, genotype, infecting organism or comorbidities. Collaboration across networks
also exists for combined protocol reviews, development of industry and investigator initiated
studies, and working groups developing consensus around novel outcome measures and
endpoint definitions. Similarly, the network has made a consistent effort to learn from
challenges experienced, and address these areas in the future; some important examples are
noted in table 3.
The development of novel or improved outcome measures remains a major focus for CF-
TDN working groups; in particular, assessing outcome measures applicable for infants and
young children as new therapies become available and decisions regarding efficacy in
younger populations must be made, for example.126 The existence of the CF Patient
Registry enhances the conduct of clinical research in many ways, and will be a pivotal tool
for implementation of comparative effectiveness research (CER) in CF. The tool has already
been used in long-term observational studies conducted through the CF-TDN.127 As this
capability grows, it is conceivable that it will allow the expansion of future CER and
observational studies to all CF care centres that participate in the registry, maximising
investigative power. Combined with the robust pipeline of therapeutics, the network is well
poised to make continued contributions to the rapid evolution of CF care.
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Cystic fibrosis transmembrane conductance regulator gene mutation classes and therapeutic
approaches under study by the cystic fibrosis Therapeutics Development Network (CF-
TDN). Note: approaches to class V (splicing mutations that alter surface CFTR levels), and
class VI (mutations in the PDZ binding domain that decrease surface stability and/or alter
recycling) CFTR mutations are under development, but have not yet entered clinical testing
through the TDN.
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Table 1




Pancrelipase Pancreatic enzyme replacement
therapy
 (Creon, Zenpep) 2009
 (Pancreaze) 2010
 (Pertzye) 2012
Aztreonam lysate for inhalation
(Cayston)
Inhaled antibiotic 2010
Ivacaftor (Kalydeco) CFTR potentiator 2012
CF, cystic fibrosis; TDN, Therapeutics Development Network.
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Table 2












1 Ivacaftor Phase II/III










PTC/other 10 Ataluren Phase III (primary
endpoint negative)
CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator; PTC, premature termination codon.
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Table 3
Lessons learned by the TDN and changes implemented to address them
Lessons learned Actions to address challenges
In an expanding network, different sites
have variable experience and knowledge
base regarding conduct of clinical
research
Defined education programmes including
self-education modules, published
standard operating procedures, etc
Variable performance in study start-up
time and enrolment rate across TDN sites
Established a central database to track
performance, provide sites real-time
feedback, annual peer comparisons of
metrics and a web-based quality
improvement programme
Variability in important clinical endpoints
and biomarkers can adversely impact
interpretation of results
Established National Resource Centres to
provide expertise in particular endpoints
and provide quality assurance to
individual TDCs. Established and
published standard operating procedures
for outcomes
Increase in number of interested
sponsors and therapeutics to be tested
creates stress on recruitment capabilities
and study throughput
Steady expansion of clinical network
through competitive renewal programme
that emphasises performance metrics
and quality study conduct
Variable experience and understanding of
CF by industry sponsors
Developed TDN sponsored consulting
programme to provide consistent advice
to sponsors and to enable rapid
development of clinical protocols
CF, cystic fibrosis; TDC, Therapeutic Development Centre; TDN, Therapeutics Development Network.
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